Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Evaluating the impact of the ‘Biosimilars Initiative’ for rheumatic conditions in British Columbia

FY 2020-21

Summary
British Columbia (BC) was the first Canadian province, and jurisdiction in North America, to institute a mandatory policy requiring individuals to be switched to biosimilars, 'Biosimilars Initiative for Prescribers'. As a result of this controversial policy, patients with rheumatic conditions (i.e. ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, or rheumatoid arthritis) were required to switch from innovator biologic drugs to less expensive biosimilar equivalents. This policy came into effect by November 2019; early estimates suggest BC may be saving $1.78 million per month from the switching policy. The objective of this research is to evaluate the policy's impact on drug use, adherence, healthcare utilization, and prescribing patterns using interrupted time series analysis (ITS). This project will utilize administrative data including BC PharmaNet, Medical Service Plan (MSP), Discharge Abstract Database (DAD), and National Ambulatory Care Reporting System (NACRS). The trainee hypothesizes that there will be increased biosimilar utilization, increased utilization of biologics with no biosimilar, no changes in adherence or healthcare utilization, and no difference in prescribing practices by geographic region or specialty after the 'Biosimilars Initiative' policy came into effect. The trainee will generate a cohort of individuals with the aforementioned rheumatic conditions. Subanalyses will be conducted according to important patient level characteristics, such as age, sex, area of residence, socioeconomic status, comorbidity burden, and polypharmacy. Prescribing patterns will be stratified by specialty and geographic location. The results of the proposed research are expected to inform the public, prescribers, and policymakers within BC and beyond.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449556
Name
McClean Alison
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the impact of the ‘Biosimilars Initiative’ for rheumatic conditions in British Columbia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biologics; Biosimilars; Healthcare Economics; Pharmaceutical Policy; Rheumatoid Arthritis
Abstract
British Columbia (BC) was the first Canadian province, and jurisdiction in North America, to institute a mandatory policy requiring individuals to be switched to biosimilars, 'Biosimilars Initiative for Prescribers'. As a result of this controversial policy, patients with rheumatic conditions (i.e. ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, or rheumatoid arthritis) were required to switch from innovator biologic drugs to less expensive biosimilar equivalents. This policy came into effect by November 2019; early estimates suggest BC may be saving $1.78 million per month from the switching policy. The objective of this research is to evaluate the policy's impact on drug use, adherence, healthcare utilization, and prescribing patterns using interrupted time series analysis (ITS). This project will utilize administrative data including BC PharmaNet, Medical Service Plan (MSP), Discharge Abstract Database (DAD), and National Ambulatory Care Reporting System (NACRS). The trainee hypothesizes that there will be increased biosimilar utilization, increased utilization of biologics with no biosimilar, no changes in adherence or healthcare utilization, and no difference in prescribing practices by geographic region or specialty after the 'Biosimilars Initiative' policy came into effect. The trainee will generate a cohort of individuals with the aforementioned rheumatic conditions. Subanalyses will be conducted according to important patient level characteristics, such as age, sex, area of residence, socioeconomic status, comorbidity burden, and polypharmacy. Prescribing patterns will be stratified by specialty and geographic location. The results of the proposed research are expected to inform the public, prescribers, and policymakers within BC and beyond.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
McClean, Alison
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~